Chicago—A major international trial will investigate whether a cholesteryl ester transfer protein (CETP) inhibitor can reduce cardiovascular risk, researchers announced during the Scientific Sessions of the American Heart Association (AHA) held here in November. The study seeks to determine whether lipid modification with anacetrapib reduces the risk of coronary death, myocardial infarction, or coronary revascularization in patients with established vascular disease who are taking a statin to treat elevated low-density lipoprotein cholesterol (LDL-C).
Mitka M. CETP Inhibition Shows Promise as Way to Reduce Cardiovascular Disease Risk. JAMA. 2011;305(2):136–137. doi:10.1001/jama.2010.1908
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: